Satralizumab 120mg Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 120mg
Reference Brands: ENSPRYNG (USA/EU)
Category: Neurology
Satralizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) pathway to reduce inflammatory activity in neuromyelitis optica spectrum disorder (NMOSD). It is indicated (as monotherapy or with immunosuppressants) for AQP4-antibody positive adults with NMOSD and is given by subcutaneous injection (loading doses at Weeks 0, 2, 4, then every 4 weeks maintenance). The approved commercial name in the US, EU and UK is ENSPRYNG and the licensed presentation is a single-use 120 mg/1 mL prefilled syringe. Common important safety notes include an increased risk of serious infections; screening for infections (including hepatitis B / TB) and vaccination status should be reviewed before starting therapy.
Satralizumab — third party manufacturing & bulk supply
Satralizumab 120mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Satralizumab is supplied as injection (prefilled syringe) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Satralizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Satralizumab →Frequently Asked Questions
Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that affects the optic nerves and spinal cord. It helps reduce inflammation and prevent relapses by blocking the interleukin-6 (IL-6) receptor, which plays a key role in the immune system’s inflammatory response.
Satralizumab is made from Satralizumab-mwge, a humanized monoclonal antibody that specifically targets the IL-6 receptor to control immune system overactivity.
The trade name of Satralizumab is Enspryng.
Satralizumab (Enspryng) is developed and manufactured by Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and marketed by Genentech in various countries.
The generic name of Satralizumab is Satralizumab-mwge.
The brand name of Satralizumab is Enspryng.
Satralizumab is manufactured in Japan and Switzerland by Chugai Pharmaceutical and Roche, and distributed globally under regulatory approvals for NMOSD treatment.
Related Products
Valproic Acid
Strength:
125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
View Details
Quick Response Guaranteed | Verified Suppliers
